GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life (as measured by time to 50% C max) in participants with obesity in the Phase Ib ...

Evolv has launched a supplement featuring yeast engineered to produce a peptide that engages GLP-1 receptors, with a half-life of 1-2 days.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC35, a once-monthly, potentially best-in-class subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) ...

- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study. - 75-day observed half-life supports ...

Here's what we know about the potentially game-changing drug right now.

BEIJING, Sept. 18, 2025 /PRNewswire/ -- Beijing QL Biopharmaceutical Co., Ltd. (hereafter "QL Biopharm" or the "company") announced today at the European Association for the Study of Diabetes (EASD) ...

GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...